aisle411 is the first-to-market mobile shopping application that allows consumers to find and map product locations in retail stores, providing users with digital coupons, product information and social gaming rewards that connect them with friends on social networks. Users can think of the application as “Google Maps inside the store for products, with social gaming rewards.” In 2010, aisle411 launched its iPhone app, and in 2011, it will launch an Android and Blackberry app. aisle411 is generating revenues from major brands and is now in 1,000 locations across the country with plans to grow to 5,000 or more locations by the end of 2011. aisle411 is the future of mobile in retail.
Akermin’s core technology is a unique methodology to protect and enable robust enzyme performance in harsh industrial environments. The company’s focus is to develop an economical enzyme-driven system to capture greenhouse gas in large industrial processes, such as flue gas from power plants. Akermin’s primary goal in 2011 is to build, test and optimize bench scale prototypes to establish systems design and confirm economic advantage. Akermin will also continue the development of its biofuel cell prototype and testing to establish final design for the military in 2011.
The Appistry CloudIQ Platform applies cloud architectures to large- scale data storage and processing challenges. CloudIQ enables "computational storage," which unifies applications and data, eliminating the gap that traditionally divides the two. By offering a new level of scalability, elasticity and reliability for data-intensive applications, Appistry allows enterprises to quickly turn raw data into actionable intelligence in a way that is faster, better and cheaper than ever before. Appistry’s customers include FedEx, government intelligence agencies, State Street Bank, GeoEye and Northrop Grumman, among others.
CardiaLen is developing a low-energy implantable atrial cardioverter for pain-free cardioversion of atrial fibrillation (AF). The company will commercialize these devices to address unmet needs in AF therapy, improve outcomes and reduce stroke and heart failure risk. Pain-free atrial cardioverters will add a new segment to the $12B global market for cardiovascular implantable devices. This device will add a new option for a significant number of drug refractory and persistent AF patients unsuited to catheter ablation. Ablation has proven to be ineffective for a high percentage of patients. Physicians, patients and insurers will enjoy shorter procedures, favorable reimbursement and lower costs.
CardiaLen successfully completed acute dog studies in 2010, and in fall 2011 expects to select its first in-man site and begin human studies.
Clearent is a payment processor whose proprietary technology and responsive support enables financial institutions, sales agents and merchants to maximize the value of their merchant services program. Clearent’s intuitive, web-based systems are simple to use and provide at-a-glance business intelligence not available from other providers. The company has consistently grown in excess of 100 percent per year and now processes over $1 billion in card volume annually.
Cogno is a multimedia children’s brand that inspires kids ages 7-13 to think critically and imaginatively in science and math. Cogno’s brand position has been described as “Star Wars” meets the “Magic School Bus.” Bill Nye The Science Guy® wrote a foreword for the Cogno novel series, and the business was featured in The Wall Street Journal. After winning 25 national product awards, the company is pursuing IP licensing in television, books and virtual word licensing.
The company continues to grow its internationally syndicated puzzlers for classrooms, now reaching over 450,000 children weekly.
Edunn Biotechnology, Inc., is a drug development company, incorporated as a Delaware corporation, operating in St. Louis. Edunn’s EDN-OL1 drug is designed to treat Alzheimer’s disease, and its second drug, EDN-OL202, is designed to treat traumatic brain injury.
Edunn won an NIH – Rapid Access to Interventional Development project award that will utilize NIH contract resources to complete manufacturing and toxicology required for EDN-OL1 to go into a Clinical Phase 1 trial. NIH-RAID usually spends $1.5 – $2.5 million per project and does not provide funds to Edunn. The company’s 2011 goals include negotiation of the first award letter ever issued by RAID and adding its project to the RAID website. Edunn will prepare regulatory documents with the preclinical NIH data and will complete a pre-IND meeting with the FDA. The company will need to provide storage of clinical supplies and will continue fundraising, including with potential investors outside of Missouri.
EndoStim, Inc. is a medical device company developing a novel treatment for severe gastroesophageal reflux disease, or GERD. EndoStim’s proprietary technology uses electrical stimulation to restore physiological function to the esophagus. The company has completed its acute studies and is currently set to gain European CE Mark of approval at the end of 2011. Approximately 12 million people in the U.S. suffer from severe GERD and lack an effective treatment. EndoStim was founded in 2009 in St. Louis, Mo. www.endostim.com
Arch Angels Investment: $610,131
Galera Therapeutics, LLC is developing agents to prevent oral mucositis, a severe side effect of radiation therapy and chemotherapy. The agents not only address a significant unmet need in prevention of oral mucositis and other side effects, but also have direct anti-cancer activity. The market opportunity for these agents is greater than $1B. The company has selected its lead clinical candidate and will be running Phase 1b/2a clinical trials in 2011 to establish human proof of concept in head and neck cancer patients undergoing radiation therapy.
Global Velocity (GV) develops advanced technology to protect valuable digital assets. GV’s products protect data in motion, including confidential and personal data such as health records, financial records, credit cards, social security numbers and any other proprietary data. GV’s first commercial product, the GV-2010, implements three integrated cybersecurity applications – data loss prevention, application control and pattern recognition – in one extremely high␣speed device.
Global Velocity has received considerable attention in light of the continuing rise of cybercrime and the WikiLeaks controversy. The Company was named a 2010 Security Innovation Network 20 Company, 2010 SC Magazine Security Innovator, 2011 CTOvision Disruptive IT List Company and 2011 MissionLink Company.
IVDiagnostics is a biomedical technology company focused on molecular diagnostics and imaging of blood borne diseases.
IVDiagnostics has completed a preclinical study on breast and colon cancer patients utilizing its IVD CTC assay, which provides physicians with a way to monitor metastatic cancer patients during and post therapy to determine the effectiveness or ineffectiveness of therapy. The company’s platform has been enhanced to permit the isolation and eradication of CTCs (Circulating Tumor Cells) in vivo. A Series A funding round is anticipated in early 2011 as plans continue for the start of FDA trials later in 2011.
LangLearner produces the world’s highest-rated and most downloaded applications for language learning and foreign communication. These applications include multimedia flashcards, games, translators, and dictionaries. The company’s latest offering provides cutting-edge HD broadcasting to mobile phones, with several applications for remote teaching, collaboration and campus security. LangLearner is quickly reaching a critical mass of users, which will make 2011 a breakthrough year. www.langlearner.com
Arch Angels Investment: $50,000
Lori Coulter developed the TrueMeasure line of apparel. Rooted in technology and fashion, Coulter’s line features wearable swimwear that flatters the figure, fits and boosts self-esteem. Coulter utilizes the TrueMeasure fit system, a process that employs light and camera-based technology; the [TC]2 3D Body Scanner, a proprietary ordering and fulfillment system, and automated CAD technology. The scanner measures the entire human body in less than 12 seconds and produces a true-to-scale 3D body model within a minute that is more accurate and consistent than measurements taken by a trained professional. The technology-based approach to fashion is an innovation in the retail industry with automated customization and rapid turnaround times.
Lori Coulter Made-to-Order Swimwear launched at select Macy’s locations in 2007 and launched a custom wholesale business targeting resorts, pageants and branded products in 2008.
Media Convergence Group, Inc., is developing multiple businesses and revenue streams generated from Newsy, a converged, digital newsroom that monitors, synthesizes and presents world news coverage. Although access to news sources is abundant, most consumers consider the news media to be biased. The consumer lacks a convenient and coherent way to comprehend, synthesize and gain understanding.
In 2010, the company made several big strides, including launching apps for the iPad and the Blackberry. Newsy is now published to seven platforms and has increased production from 75 news stories per month to 325 news stories per month.
The company’s progress has resulted in 4+ (out of 5) star ratings for Newsy apps across all platforms. In 2011, the company expects to see substantial revenue growth. Revenue will continue to be generated via paid advertising and content syndication, and custom content will generate a new revenue stream.
Pulse Therapeutics is developing a medical device that will significantly increase the efficacy of clot busting drugs for the ER-based IV treatment of stroke. In 2010, Pulse concluded pre-clinical studies in animal models, which demonstrated magnetic iron particles, when controlled by a compact external magnet, accelerates blood diffusion and allows a clot-busting drug to reach a clot more quickly and at higher concentrations, resulting in significantly faster reprofusion compared to standard IV delivery. Pulse will provide a relatively inexpensive proprietary magnet and low-cost injectable magnetic particles to ER physicians which will require little operator training. Since Pulse’s technology is administered in the ER, hospitals will likely be able to recognize greater profits per procedure.
Arch Angels Investment: $75,000
Sequoia Sciences is a pharmaceutical company commer- cializing new medicines to treat bacterial infections. Pro- grams consist of small molecules targeting the lung infections of cystic fibrosis patients and MRSA infec- tions, and vaccines for the treatment of recurrent urinary tract infections (UTI). Sequoia also has an unparalleled collection of structurally diverse natu- ral product compounds isolated from plants collected by the Missouri Botanical Garden.
In 2010, Sequoia completed most of the pre-IND work necessary to start clinical trials in 2011 on its UTI compound. Phase I of the clinical trial will be conducted in Florida and will include an early look at efficacy.
Sequoia also signed a licensing deal with Amgen that should result in significant revenues over the next several years.
SOMARK’s goal is to improve life sciences research processes with an advanced lab-animal identification system. A more reliable and more humane ID system can provide higher quality preclinical data that can translate into safer treatments and a shorter development period. SOMARK wants to help researchers create safer, cheaper and more effective treatments. In 2010, the company secured more capital, completed successful customer pilots, commenced manufacturing, secured purchase orders and hired its first sales representatives. In 2011, SOMARK will initiate shipment of its first product, the Labstamp System.
TeraVista Systems provides corporations with a unique toolset of technologies that streamline their environ- mental and energy practices, thereby saving time and money. Its patent-pending CarbonTrax software is designed to automate the verification, validation and aggregation of carbon credits for all aggregation companies and financial institutions. Only 10 percent of current credits are being spot-validated, but CarbonTrax solves this problem through remote sensing technologies that allow for 90 percent validation.
Traxxsson is developing new blood tests for diagnosing and tracking the course of cancer and psychiatric diseases. Mammograms and PSA tests often wrongly indicate the presence of cancer, so Traxxsson’s CancSureTM Verification tests are intended to confirm if cancer is present, with- out subjecting patients to painful biopsies. Additionally, the company is developing its own CancSureTM Screening blood test to find most cancers and identify their bodily location. Because there are no commercial blood tests to diagnose psychiatric diseases, Traxxsson is also developing a blood test that can identify 70 percent of the patients that have schizophrenia. In addition to di- agnosis, this test may determine the effectiveness of treatment, and assist in the development of new psychiatric drugs.
Arch Angels Investment: $50,000
U.S. SPINE, INC.
In 2010, U.S. Spine was acquired by Amedica Corporation (AC), a spinal and orthopedic implant and instrument company focused on unique silicon ni- tride (SiN) ceramic technologies.